💊 Sitryx reached a huge milestone last week, announcing the initiation of a first-in-human clinical trial for the treatment of atopic dermatitis – a chronic skin disease affecting over 200 million people worldwide. Sitryx is evaluating their treatment, named SYX-5219, as a potential disease-modifying therapy. As it stands, preclinical data has shown it reduces inflammation and enhances skin barrier repair. More than five million people in the US and Europe are living with a moderate to severe form of the disease, with symptoms that massively impact quality of life. It’s fantastic to see Sitryx’s progress in advancing a treatment to solve this problem. Read more about the trial here ➡️ https://lnkd.in/ecJatRFx #FirstInHuman #ClinicalTrial
Oxford Science Enterprises, It's amazing to see Sitryx making strides in treating atopic dermatitis! This will surely make a difference for so many people. I'm excited to hear more about how SYX-5219 performs in the trial. How do you think this treatment could change the lives of those affected? 💙💊 #AtopicDermatitis #ClinicalTrials